Bioasis Technologies (TSXV:BTI) Dividends per Share : C$0.00 (TTM As of Nov. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Bioasis Technologies Dividends per Share?

Bioasis Technologies's dividends per share for the three months ended in Nov. 2022 was C$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Nov. 2022 was C$0.00. Its Dividend Payout Ratio for the three months ended in Nov. 2022 was 0.00. As of today, Bioasis Technologies's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Bioasis Technologies Dividends per Share Historical Data

The historical data trend for Bioasis Technologies's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Dividends per Share Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Dividends per Share

Get a 7-Day Free Trial

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Bioasis Technologies's Dividends per Share

For the Biotechnology subindustry, Bioasis Technologies's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Dividend Yield % falls into.

Bioasis Technologies Dividends per Share Calculation

Dividends paid to per common share.

Bioasis Technologies (TSXV:BTI) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Bioasis Technologies's Dividend Payout Ratio for the quarter that ended in Nov. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Nov. 2022 )	/	EPS without NRI (Q: Nov. 2022 )
	=	0	/	-0.009
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Bioasis Technologies Dividends per Share Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (TSXV:BTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (TSXV:BTI) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.